Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) is trading at $3.58, about ₹343 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 0.28% today. Indian residents can buy Bolt Biotherapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$3.58
Today's high
$3.68
52 week low
$3.10
52 week high
$7.20
BOLT opened at $3.60, closed previously at $3.59, and has traded between $3.10 and $7.20 over the past 52 weeks.
About
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Key statistics
Avg. volume
28.16K
Market cap
$6.88M
P/E Ratio
-0.22
Price-to-sales ratio
1.46
Enterprise value
$15.64M
Free cash flow yield
-458.42%
Debt-to-equity ratio
1.71
Return on equity
-126.23%
ROIC
-82.33%
Beta
1.09
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$7.70M
Earnings per share
-$17.85
Free cash flow
-$39.92M
Net profit margin
-611.47%
Gross margin
95.68%
EBITDA
-$31.89M
Revenue growth
0.07%
Similar securities
This is not an investment recommendation
How to buy Bolt Biotherapeutics from India
Indian residents can buy Bolt Biotherapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Bolt Biotherapeutics and place an order
Find Bolt Biotherapeutics by name or by its ticker, BOLT, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Bolt Biotherapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Bolt Biotherapeutics position in USD and INR. Bolt Biotherapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Bolt Biotherapeutics from India
Trading and taxes when buying Bolt Biotherapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBolt Biotherapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Bolt Biotherapeutics stock?
Yes. Bolt Biotherapeutics (BOLT) has been listed on NASDAQ since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Bolt Biotherapeutics share cost in rupees?
One Bolt Biotherapeutics share is $3.58 — about ₹343 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Bolt Biotherapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Bolt Biotherapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Bolt Biotherapeutics?
Yes. One Bolt Biotherapeutics share is $3.58, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Bolt Biotherapeutics.
How are gains on Bolt Biotherapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Bolt Biotherapeutics price. Paasa issues a capital-gains statement for your return.
Does Bolt Biotherapeutics pay a dividend?
No. Bolt Biotherapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Bolt Biotherapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Bolt Biotherapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Bolt Biotherapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Bolt Biotherapeutics holding, its cost and its closing value.
How do I sell Bolt Biotherapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.